SCHEMBL181563

SCHEMBL181563

O=C1CC(c2ccccc2)(c2ccccc2)c2ccccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.48
GOPC Q9HD26 1/20 0.48
KDM4E B2RXH2 1/20 0.41
POLB P06746 2/20 0.38
NPC1 O15118 1/20 0.38
GAA P10253 3/20 0.38
NPSR1 Q6W5P4 2/20 0.38
LMNA P02545 3/20 0.37
PKM P14618 1/20 0.37
RXFP1 Q9HBX9 1/20 0.36
HSP90AA1 P07900 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
MAPT P10636 2/20 0.36
RAB9A P51151 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
ESR1 P03372 1/20 0.36
TP53 P04637 1/20 0.36
TYMS P04818 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30074263 1.00 CFTR (0.48) CFTRGOPCKDM4EPOLBNPC1
SCHEMBL6552460 0.90 ESR1 (0.51) CFTRGOPCKDM4EPOLBGAA
SCHEMBL6550908 0.90 CFTR (0.41) CFTRGOPCKDM4EPOLBNPC1
Propionic Acid SCHEMBL4796324 0.87 PKM (0.41) CFTRGOPCKDM4EGAANPSR1
SCHEMBL6550929 0.86 MAPT (0.46) CFTRGOPCNPC1NPSR1SMN1; SMN2
SCHEMBL28609498 0.85 PGR (0.38) CFTRGOPCPOLBLMNASMN1; SMN2
SCHEMBL28606394 0.85 MDM2 (0.40) CFTRGOPCPOLBNPSR1LMNA
SCHEMBL14462993 0.85 S100A4 (0.42) CFTRGOPCPOLBHSP90AA1SMN1; SMN2
SCHEMBL28610336 0.81 NPSR1 (0.57) CFTRGOPCPOLBGAANPSR1
SCHEMBL28357232 0.80 MAPT (0.44) CFTRGOPCKDM4EPOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109180446-A A kind of synthetic method of 2,3- diphenyl -1H- 1-Indanone derivative 吉林化工学院 2019-01-11 CN claimed
US-20020004519-A1 METHOD FOR REDUCING CHLORIDE SECETION BY INTESTINAL EPITHLIAL CELLS IN SITU LENCER WAYNE I (US) 2002-01-10 US claimed
JP-2001523717-A 2001-11-27 JP claimed
EP-1032385-A1 USE OF SUBSTITUTED DIPHENYL INDANONE, INDANE AND INDOLE COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SICKLE CELL DISEASE, INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELLPROLIFERATION, DIARRHE AND SCOURS CHILDREN'S MEDICAL CENTER CORPORATION (US) 2000-09-06 EP claimed
WO-1999026624-A1 USE OF SUBSTITUTED DIPHENYL INDANONE, INDANE AND INDOLE COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SICKLE CELL DISEASE, INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION, DIARRHE AND SCOURS CHILDREN'S MEDICAL CENTER CORPORATION (US) 1999-06-03 WO claimed
EP-4263544-B1 INDOLO[3.2.1-JK]CARBAZOLE-6-CARBONITRILE DERIVATIVES AS BLUE EMITTERS IN OLEDS UDC IRELAND LTD (IE) 2026-05-13 EP disclosed
US-12628554-B2 Photoelectric conversion element, imaging element, optical sensor, and compound FUJIFILM CORPORATION (JP) 2026-05-12 US disclosed
US-12568754-B2 Laminate comprising a wavelength-conversion material and a wavelength-selective absorption layer, display device, and organic electroluminescent display device FUJIFILM CORPORATION (JP) 2026-03-03 US disclosed
EP-4676208-A2 NITROGEN-CONTAINING HETERO-AROMATICS FOR ORGANIC ELECTROLUMINESCENT DEVICES Merck Patent GmbH (DE) 2026-01-07 EP disclosed
US-20250393473-A1 PHOTOELECTRIC CONVERSION ELEMENT, IMAGING ELEMENT, AND OPTICAL SENSOR FUJIFILM CORP (JP) 2025-12-25 US disclosed
US-20250374741-A1 PHOTOELECTRIC CONVERSION ELEMENT, IMAGING ELEMENT, OPTICAL SENSOR, AND COMPOUND FUJIFILM CORP (JP) 2025-12-04 US disclosed
US-12479989-B2 Wavelength selective absorption filter and organic electroluminescent display device FUJIFILM CORPORATION (JP) 2025-11-25 US disclosed
EP-1047411-A1 SUBSTITUTED DIPHENYL INDANONE, INDANE AND INDOLE COMPOUNDS AND ANALOGUES THEREOF USEFUL FOR THE TREATMENT OR PREVENTION OF DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2000-11-02 EP disclosed
EP-1047411-A1 SUBSTITUTED DIPHENYL INDANONE, INDANE AND INDOLE COMPOUNDS AND ANALOGUES THEREOF USEFUL FOR THE TREATMENT OR PREVENTION OF DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2000-11-02 EP disclosed
EP-1032385-A1 USE OF SUBSTITUTED DIPHENYL INDANONE, INDANE AND INDOLE COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SICKLE CELL DISEASE, INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELLPROLIFERATION, DIARRHE AND SCOURS CHILDREN'S MEDICAL CENTER CORPORATION (US) 2000-09-06 EP disclosed
EP-1032385-A1 USE OF SUBSTITUTED DIPHENYL INDANONE, INDANE AND INDOLE COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SICKLE CELL DISEASE, INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELLPROLIFERATION, DIARRHE AND SCOURS CHILDREN'S MEDICAL CENTER CORPORATION (US) 2000-09-06 EP disclosed
WO-1999026611-A1 SUBSTITUTED DIPHENYL INDANONE, INDANE AND INDOLE COMPOUNDS AND ANALOGUES THEREOF USEFUL FOR THE TREATMENT OR PREVENTION OF DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1999-06-03 WO disclosed
WO-1999026624-A1 USE OF SUBSTITUTED DIPHENYL INDANONE, INDANE AND INDOLE COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SICKLE CELL DISEASE, INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION, DIARRHE AND SCOURS CHILDREN'S MEDICAL CENTER CORPORATION (US) 1999-06-03 WO disclosed
WO-1999026624-A1 USE OF SUBSTITUTED DIPHENYL INDANONE, INDANE AND INDOLE COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SICKLE CELL DISEASE, INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION, DIARRHE AND SCOURS CHILDREN'S MEDICAL CENTER CORPORATION (US) 1999-06-03 WO disclosed
WO-1999026611-A1 SUBSTITUTED DIPHENYL INDANONE, INDANE AND INDOLE COMPOUNDS AND ANALOGUES THEREOF USEFUL FOR THE TREATMENT OR PREVENTION OF DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1999-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12568754-B2 Laminate comprising a wavelength-conversion material and a wavelength-selective absorption layer, display device, and organic electroluminescent display device STRA6, CDH1, EPCAM CFTR 4149/4885GOPC 1845/4885KDM4E 657/4885
US-20020004519-A1 METHOD FOR REDUCING CHLORIDE SECETION BY INTESTINAL EPITHLIAL CELLS IN SITU SLC10A2, VIP, SLC26A3 CFTR 128/4885GOPC 2332/4885KDM4E 1852/4885
US-20250393473-A1 PHOTOELECTRIC CONVERSION ELEMENT, IMAGING ELEMENT, AND OPTICAL SENSOR NR2E3, CRY1, CRY2 CFTR 1746/4885GOPC 3162/4885KDM4E 2101/4885
US-12628554-B2 Photoelectric conversion element, imaging element, optical sensor, and compound SCO2, CRY2, PYM1 CFTR 2708/4885GOPC 983/4885KDM4E 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.